■ LECTURE OVERVIEW: Pompe Disease (Glycogen Storage Disease Type II) is a lysosomal storage disease that impairs the degradation of a small fraction of cellular glycogen, leading to multi-organ tissue destruction.
■ METABOLIC INFRASTRUCTURE:
1. Enzymatic Void: Autosomal recessive deficiency of Lysosomal Acid Alpha-1,4-Glucosidase (also called acid maltase).
2. Compartment Sequestration: Unlike other glycogen storage diseases, the defect is localized within lysosomes, which take up intracellular glycogen via autophagy but are unable to hydrolyze its alpha-1,4 and alpha-1,6 linkages.
3. Intralysosomal Glycogen Aggregation: Glycogen accumulates selectively within lysosomal vacuoles of major metabolically active tissues, primarily cardiac, skeletal, and smooth muscle fibers.
4. Myofibril Displacement: Cellular organelles are displaced, and myofibrillar architecture is completely disrupted by hypertrophying lysosomes, causing early muscle destruction.
■ PHARMACOKINETIC & PHARMACODYNAMIC ATTRIBUTES:
Absorption and steady-state kinetics display high variability based on plasma protein binding levels, tissue volume of distribution (Vd), and hepatic CYP450 microsomal enzymatic clearance indices.
■ SURGICAL COMPASS & ANATOMICAL CORRELATION:
Dissection lines must respect established fascial boundaries to prevent neurovascular traction injuries and secure excellent diagnostic margins.
[HY-BOARD-1192]
🌟 Dynamic Clinical Key:
Infantile-onset Pompe disease presents with a classic triad: profound hypotonia (floppy infant), macroglossia, and massive hypertrophic cardiomyopathy resulting in early cardiorespiratory failure. 'Pompe trashes the Pump'—unlike other GSDs, patients have normal blood glucose levels as cytoplasmic glycogenolysis is fully intact. Closely monitor serum plasma concentrations if drugs display a narrow therapeutic window to mitigate toxic peaks. Verify landmarks dynamically with gentle palpation and specialized intraoperative markers.